Drugs Information Online
Drugs and diseases reference index

Drugs and diseases reference index

Drugs A-Z List

Diseases & Conditions A-Z List

Herbs & Supplements

Medical Dictionary

Full Article

Popular Drugs

Popular Diseases & Conditions

Drugs reference index «Olmesartan Medoxomil/Hydrochlorothiazide»

Olmesartan Medoxomil / Hydrochlorothiazide

Pronunciation: (ol-me-SAR-tan me-DOX-oh-mil/HYE-droe-KLOR-oh-THYE-a-zide)Class: Antihypertensive combination

Trade Names:Benicar HCT- Tablets olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg- Tablets olmesartan medoxomil 40 mg and hydrochlorothiazide 12.5 mg- Tablets olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg

Indications and Usage

Treatment of hypertension.


Anuria; hypersensitivity to sulfonamide-derivatives or any component of the product.

Dosage and Administration


PO Titrate the dose based on individual response to each component as monotherapy. The dosage range for olmesartan/hydrochlorothiazide is 10 mg/12.5 mg to 40 mg/25 mg once daily.

Olmesartan: The usual starting dosage of olmesartan is 20 mg once daily as monotherapy. If further reduction of BP is needed after 2 wk of therapy, the dose may be increased to 40 mg. If BP is not controlled by olmesartan alone, hydrochlorothiazide may be added, starting with 12.5 mg and then titrating to 25 mg once daily.

Hydrochlorothiazide: If a patient is taking hydrochlorothiazide, olmesartan may be added, starting with 20 mg once daily and titrating to 40 mg. Consider reducing larger doses of hydrochlorothiazide to 12.5 mg before adding olmesartan.

Renal Function ImpairmentAdults

PO If CrCl is over 30 mL/min, the usual regimens of olmesartan/hydrochlorothiazide may be followed. In more severe renal function impairment, olmesartan/hydrochlorothiazide is not recommended.

General Advice

  • May be given with other antihypertensive agents.
  • May be given with or without food.
  • Depending on the BP, the dose may be titrated at 2 to 4wk intervals.


Store at 68° to 77°F.

Drug Interactions

Alcohol, barbiturates, narcotics

Potentiation of orthostatic hypotension may occur.

Antidiabetic agents (oral agents and insulin)

Dosage adjustments of the antidiabetic agent may be needed.

Antihypertensive agents

Effects may be additive or potentiated.

Cholestyramine, colestipol

Hydrochlorothiazide absorption may be reduced up to 85%.


Increased risk of electrolyte depletion (eg, hypokalemia).


Increased risk of lithium toxicity caused by reduced clearance. Do not coadminister.

Nondepolarizing skeletal muscle relaxants (eg, tubocurarine)

Effect of muscle relaxant may be enhanced.

NSAIDs (eg, ibuprofen)

The antihypertensive effect of hydrochlorothiazide may be reduced.

Pressor amines (eg, norepinephrine)

Effect of pressor amine may be reduced.

Laboratory Test Interactions

Hydrochlorothiazide may decrease serum protein-bound iodine levels without signs of thyroid disturbance; may cause diagnostic interference of serum electrolyte levels, blood and urine glucose levels, serum bilirubin levels, and serum uric acid levels; may cause intermittent and slight elevations in serum calcium without known disorders of calcium metabolism.

Adverse Reactions


Dizziness (9%); vertigo (greater than 1%); asthenia (postmarketing).


Rash (greater than 1%); alopecia, pruritus, urticaria (postmarketing).


Nausea (3%); abdominal pain, diarrhea, dyspepsia, gastroenteritis (greater than 1%); vomiting (postmarketing).


Hematuria (greater than 1%); acute renal failure, increased blood creatinine levels (postmarketing).


Increased AST, ALT, and glucose tolerance test (greater than 1%).

Lab Tests

Increased BUN and serum creatinine (1%).


Hyperuricemia (4%); increased creatine phosphokinase, hyperglycemia, hyperlipidemia (greater than 1%).


Arthralgia, arthritis, back pain, myalgia (greater than 1%); rhabdomyolysis (postmarketing).


Upper respiratory tract infection (7%); coughing (greater than 1%).


Chest pain, peripheral edema (greater than 1%); angioedema (postmarketing).



Can cause injury and death to the developing fetus when used during the second and third trimester of pregnancy.


Perform periodic determinations of serum electrolytes to detect possible electrolyte imbalance.


Category C (first trimester); Category D (second and third trimesters).




Safety and efficacy not established.


Use with caution, usually starting at the low end of the dosage range, because of the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapy.


May occur in patients with or without a history of allergy or bronchial asthma.

Renal Function

Not recommended in patients with severe renal function impairment; cumulative effects may develop in patients with impaired renal function.

Hepatic Function

Use with caution in patients with impaired hepatic function or progressive liver disease.


Hyperglycemia may occur; latent diabetes mellitus may become manifest.


Hyperuricemia or frank gout may be precipitated.

Lipid disorders

Increases in cholesterol and triglyceride levels may occur.

Systemic lupus erythematosus

Activation or exacerbation may occur.

Volume or salt depletion

Symptomatic hypotension may occur after initiation of treatment in patients with an activated renin-angiotensin system (eg, volume- or salt-depleted patients).



Bradycardia, dehydration, electrolyte depletion (ie, hypochloremia, hypokalemia, hyponatremia), hypotension, tachycardia.

Patient Information

  • Advise patient to read the patient information material before using product for the first time and with each refill.
  • Instruct patient regarding how to store, administer, and dispose of outdated medication.
  • Caution patients to inform health care provider if light-headedness occurs. If syncope occurs, the drug should be stopped until the health care provider is contacted.
  • Instruct patient to take exactly as prescribed and not to change the dose or discontinue therapy unless advised by health care provider.

Copyright © 2009 Wolters Kluwer Health.